Blood, 1 December 2002, Vol. 100, No. 12, pp. 4243-4244
CORRESPONDENCE
To the editor:
ETO sequence may be dispensable in some AML1-ETO leukemias
Acute myeloid leukemia (AML) is a heterogeneous disease, with
individual cases showing variability in clinical presentation, blast-cell morphology, therapeutic response, and long-term prognosis. One of the most common cytogenetic abnormalities described in AML is
t(8;21)(q22;q22) found in 10% to 15% of cases.1 As a consequence of the chromosomal translocation, 5 exons of the AML-1 gene are fused to nearly the entire coding sequence of the ETO gene, generating an easily detectable polymerase chain reaction (PCR) product of a constant size (260 bp), corresponding to an in-frame fusion of AML1 exon 5 to ETO exon 2. This novel chimeric gene,
AML/ETO, encodes a fusion protein with a primary inhibitory role in the
normal hematopoietic differentiation program.
Adult patients with de novo-diagnosed AML enrolled in the Spanish
Estudi i Tractament de Leucèmies Agudes i Mielodisplàssies (CETLAM) 99 protocol were tested for the presence of chimeric AML1-ETO and CBF
-MYH11 mRNA using the BIOMED-1 protocols. Briefly, 1 µg of RNA obtained from fresh leukemic bone marrow was
retrotranscribed into cDNA using random hexamers. RNA quality
assessment was carried out with 5 µL of cDNA in a
1-step PCR amplification of the normal ABL. cDNA (3 µL) was
used for the first-step amplification using specific primers for the
AML1-ETO fusion gene transcript, followed by a second-step (nested)
amplification. Amplified PCR products from PCR I and II were separated
by electrophoresis on a 2% agarose gel.
In one patient with a typical M2 leukemia with the
t(8;21)(q22;q22), a different-sized PCR amplimer was observed. This
faster migrating band was cut from the gel and used for reamplification by PCR. The sequence of this purified product revealed a 50-bp frameshift deletion in exon 2 of ETO. The loss of 50 bp originated a
disruption of the reading frame of this transcript resulting in the
introduction of a premature stop codon 41 amino acid
downstream (Figure 1). The encoded truncated protein would only conserve 31 residues from the
ETO coding sequence, and 24 residues would be different from the
original transcript as a consequence of the disruption of the reading
frame.
View larger version (35K):
[in this window]
[in a new window]
| Figure 1.
Eto deletion in one AML1-ETO leukemia case.
(A) AML1-ETO RT-PCR disclosed an abnormal band that was smaller than
the typical specific product. M indicates molecular weight
marker; C+, positive control; C , blank sample; and P,
patient. (B) Direct sequencing of the abnormal PCR product revealed a
50-bp ETO deletion. (C) Diagram representation of the 50-bp deletion.
Only 7 residues of the ETO sequence are conserved in this abnormal
chimeric product.
|
|
To date, a few alternatively spliced out-of-frame variants consisting
of additional small ETO alternative exons have been described.2,3
In the case under discussion, the reverse transcriptase
(RT)-PCR showed a single band, which indicates the presence
in this patient of a unique transcript.
The expression of this abnormal transcript was investigated through the
evolution of the disease by means of real-time quantitative PCR
following the recommendations of the European SANCO (Health and
Consumer Protection, European Commission) Concerted Action using the ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster
City, CA).4 Based on these findings, fusion transcript values obtained were normalized with respect to the number of ABL
transcripts and expressed as fusion-gene copy number per
104 copies of ABL. At the time of diagnosis, the real-time
PCR showed 28 000 copy number of
[AML1-ETO/abl]× 104, and after therapy the
transcript levels rapidly decreased to 1.3 copies. This parallels with
the results obtained in typical AML1-ETO fusion cases.
The AML1-ETO fusion protein retains many of the important functional
domains of both AML1 and ETO, including the RHD (Runt homology
DNA-binding domain) of AML1, and the ETO sequences that mediate homo-
and heterodimerization with ETO/MTG family members and
interaction with nuclear corepressors. The ability of AML1-ETO to
repress transcription is dependent on both the RHD of AML1, and the
hydrophobic heptad repeat (HHD) and zinc fingers of
ETO.5-7 In the patient described here, the
fusion-truncated protein would not have any of the most important ETO
domains, and thus it shows that most of the ETO sequence may be
dispensable in this AML1-ETO leukemia.
The fact that the patient had a typical M2 leukemia may be explained by
the determinant effect on the leukemic phenotype of cooperative and yet
unidentified mutations associated with the AML1-ETO
rearrangement.8
Adriana Lasa, Josep F. Nomdedéu, Maria J. Carnicer, Andreu Llorente, and Jorge Sierra
Correspondence: Josep F. Nomdedéu, Laboratori
d'Hematologia, Hospital de la Santa Creu i Sant Pau, Avda Sant Antoni
M. Claret, 167, 08025 Barcelona, Spain; e-mail:
jnomdedeu{at}hsp.santpau.es
References
1.
Downing JR.
The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance.
Br J Haematol.
1999;106:296-308[CrossRef][Medline]
[Order article via Infotrieve].
2.
Tighe JE, Calabi F.
Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivated (8) chromosome in the (8;21) of acute myeloid leukemia M2.
Blood.
1994;84:2115-2121[Abstract/Free Full Text].
3.
Van der Locht LT, Smetsers TF, Wittebol S, et al.
Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia.
Leukemia.
1994;8:1780-1784[Medline]
[Order article via Infotrieve].
4. Beillard E, van der Velden V, Bi W, et al. Standardization and quality
control studies of `real-time' quantitative reverse transcriptase
polymerase chain reaction (RQ-PCR) of fusion gene transcripts for
minimal residual disease detection in leukemia - A Europe Against
Cancer Program. 2002. Leukemia. In press.
5.
Speck NA, Gilliland DG.
Core-binding factors in haematopoiesis and leukaemia.
Nature Cancer Rev.
2002;2:502-513.
6.
Amann JM, Nip J, Strom DK, et al.
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Mol Cell Biol.
2001;21:6470-6483[Abstract/Free Full Text].
7.
Hug BA, Lee S, Kinsler E, et al.
Cooperative function of AML1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells.
Cancer Res.
2002;62:2906-2912[Abstract/Free Full Text].
8.
Yuan Y, Zhou L, Miyamoto T, et al.
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutation.
Proc Natl Acad Sci U S A.
2001;98:10398-10403[Abstract/Free Full Text].
